Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals, Inc. on March 4, 2010. The report covers corporate governance actions and shareholder meeting announcements effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on executive compensation adjustments and corporate events rather than financial performance data.
Material Changes
- Executive Compensation: The Board of Directors amended the Company's Cash Bonus Plan to increase the annual bonus target for Bruce C. Cozadd, Chairman and Chief Executive Officer, from 50% to 60% of his annual base salary. This change applies to the calendar year commencing January 1, 2010.
- Corporate Governance: The amendment was made upon the recommendation of the Compensation Committee. Actual bonus amounts remain at the discretion of the Committee based on corporate and individual performance.
Guidance, Outlook, and Other Events
- Annual Meeting: The 2010 Annual Meeting of Stockholders is scheduled for June 7, 2010, at 10:00 a.m. local time at the Company's facilities in Palo Alto, California.
- Record Date: Stockholders of record as of the close of business on April 14, 2010, are entitled to notice of and to vote at the Annual Meeting.
- Exhibits: The amended Bonus Plan will be filed as an exhibit to the Company's quarterly report on Form 10-Q for the period ending March 31, 2010.
Key Facts for Investor Verification
- Verify the specific performance metrics tied to the increased bonus target for the CEO in the upcoming 10-Q filing.
- Confirm the agenda and proxy statement details for the June 7, 2010 Annual Meeting.
- Review the full text of the amended Cash Bonus Plan (Exhibit 10.71) for terms applicable to other executive officers.